Public health impact of RSV vaccination among adults aged 60 years and older in the United States using real-world evidence from the initial post-introduction season
Background Respiratory syncytial virus (RSV) is an important cause of severe respiratory illness in older adults and adults with certain health conditions. Adjuvanted RSVPreF3 and non-adjuvanted RSVpreF vaccines were approved in 2023 for use in adults aged ≥60 years in the United States (US). This s...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2025.2539893 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839612455966212096 |
|---|---|
| author | Frederik Verelst David Singer Jonathan Graham Mei Grace Elizabeth La Eliana Biundo |
| author_facet | Frederik Verelst David Singer Jonathan Graham Mei Grace Elizabeth La Eliana Biundo |
| author_sort | Frederik Verelst |
| collection | DOAJ |
| description | Background Respiratory syncytial virus (RSV) is an important cause of severe respiratory illness in older adults and adults with certain health conditions. Adjuvanted RSVPreF3 and non-adjuvanted RSVpreF vaccines were approved in 2023 for use in adults aged ≥60 years in the United States (US). This study explored the impact of RSV vaccination during the first season of vaccine availability.Research design and methods A Markov model was adapted to compare RSV-related outcomes in adults aged ≥60 years with or without RSV vaccination. Analyses were based on real-world RSV vaccination uptake and effectiveness in the 2023-2024 season. Scenario analyses assumed the same higher uptake as for influenza vaccines.Results Over 1 year, real-world RSV vaccinations were estimated to avert 18,326 RSV-related emergency department (ED) visits 23,630 hospitalizations, and 1,930 deaths versus no vaccination. Assuming the same uptake as for influenza vaccines resulted in considerable additional RSV disease burden averted (avoiding a total of 65,740 RSV-related ED visits 84,551 hospitalizations, and 6,838 deaths over 1 year vs. no vaccination).Conclusions Findings suggest that real-world RSV vaccinations have substantially reduced RSV disease burden in the US. Increasing RSV vaccination uptake among eligible adults aged ≥60 years could provide additional public health benefits. |
| format | Article |
| id | doaj-art-dcd5ab2d8f9743f19b18ebd6b1eb90d4 |
| institution | Matheson Library |
| issn | 1476-0584 1744-8395 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj-art-dcd5ab2d8f9743f19b18ebd6b1eb90d42025-07-28T09:13:13ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952025-12-0110.1080/14760584.2025.2539893Public health impact of RSV vaccination among adults aged 60 years and older in the United States using real-world evidence from the initial post-introduction seasonFrederik Verelst0David Singer1Jonathan Graham2Mei Grace3Elizabeth La4Eliana Biundo5GSKWavre, BelgiumGSKPhiladelphia, PA, USARTI Health Solutions, Research Triangle ParkNC, USARTI Health Solutions, Research Triangle ParkNC, USAGSKPhiladelphia, PA, USAGSKWavre, BelgiumBackground Respiratory syncytial virus (RSV) is an important cause of severe respiratory illness in older adults and adults with certain health conditions. Adjuvanted RSVPreF3 and non-adjuvanted RSVpreF vaccines were approved in 2023 for use in adults aged ≥60 years in the United States (US). This study explored the impact of RSV vaccination during the first season of vaccine availability.Research design and methods A Markov model was adapted to compare RSV-related outcomes in adults aged ≥60 years with or without RSV vaccination. Analyses were based on real-world RSV vaccination uptake and effectiveness in the 2023-2024 season. Scenario analyses assumed the same higher uptake as for influenza vaccines.Results Over 1 year, real-world RSV vaccinations were estimated to avert 18,326 RSV-related emergency department (ED) visits 23,630 hospitalizations, and 1,930 deaths versus no vaccination. Assuming the same uptake as for influenza vaccines resulted in considerable additional RSV disease burden averted (avoiding a total of 65,740 RSV-related ED visits 84,551 hospitalizations, and 6,838 deaths over 1 year vs. no vaccination).Conclusions Findings suggest that real-world RSV vaccinations have substantially reduced RSV disease burden in the US. Increasing RSV vaccination uptake among eligible adults aged ≥60 years could provide additional public health benefits.https://www.tandfonline.com/doi/10.1080/14760584.2025.2539893Public health impactrespiratory syncytial virusvaccinationUnited StatesMarkov model |
| spellingShingle | Frederik Verelst David Singer Jonathan Graham Mei Grace Elizabeth La Eliana Biundo Public health impact of RSV vaccination among adults aged 60 years and older in the United States using real-world evidence from the initial post-introduction season Expert Review of Vaccines Public health impact respiratory syncytial virus vaccination United States Markov model |
| title | Public health impact of RSV vaccination among adults aged 60 years and older in the United States using real-world evidence from the initial post-introduction season |
| title_full | Public health impact of RSV vaccination among adults aged 60 years and older in the United States using real-world evidence from the initial post-introduction season |
| title_fullStr | Public health impact of RSV vaccination among adults aged 60 years and older in the United States using real-world evidence from the initial post-introduction season |
| title_full_unstemmed | Public health impact of RSV vaccination among adults aged 60 years and older in the United States using real-world evidence from the initial post-introduction season |
| title_short | Public health impact of RSV vaccination among adults aged 60 years and older in the United States using real-world evidence from the initial post-introduction season |
| title_sort | public health impact of rsv vaccination among adults aged 60 years and older in the united states using real world evidence from the initial post introduction season |
| topic | Public health impact respiratory syncytial virus vaccination United States Markov model |
| url | https://www.tandfonline.com/doi/10.1080/14760584.2025.2539893 |
| work_keys_str_mv | AT frederikverelst publichealthimpactofrsvvaccinationamongadultsaged60yearsandolderintheunitedstatesusingrealworldevidencefromtheinitialpostintroductionseason AT davidsinger publichealthimpactofrsvvaccinationamongadultsaged60yearsandolderintheunitedstatesusingrealworldevidencefromtheinitialpostintroductionseason AT jonathangraham publichealthimpactofrsvvaccinationamongadultsaged60yearsandolderintheunitedstatesusingrealworldevidencefromtheinitialpostintroductionseason AT meigrace publichealthimpactofrsvvaccinationamongadultsaged60yearsandolderintheunitedstatesusingrealworldevidencefromtheinitialpostintroductionseason AT elizabethla publichealthimpactofrsvvaccinationamongadultsaged60yearsandolderintheunitedstatesusingrealworldevidencefromtheinitialpostintroductionseason AT elianabiundo publichealthimpactofrsvvaccinationamongadultsaged60yearsandolderintheunitedstatesusingrealworldevidencefromtheinitialpostintroductionseason |